Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
|
|
- Cora Bennett
- 5 years ago
- Views:
Transcription
1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No.: Title: A Phase III open-label, non-comparative study of BRL25000 ES-600 in paediatric patients with otitis media Rationale: In Japan, as in the United States and other countries, separation of S. pneumoniae clinical isolates highly resistant to CVA/AMPC (e.g., MIC 4 µg/ml) from pediatric patients with infection has been reported. It is important to provide a treatment choice that is effective against current drug-resistant bacteria and against bacterial strains that are likely to increase in the future. Under the circumstances, we conducted a clinical study of BRL25000 ES-600 in pediatric patients with acute otitis media in Japan at the dosage of CVA 6.4 mg/kg/day and AMPC 90 mg/kg/day, which is the same as in the United States. Phase: III Study Period: 6-Jan Apr-2003 Study Design: Multicenter, open-label, non-comparative study Centres: 12 centres in Japan Indication: Paediatric patients with otitis media Treatment: After enrolled in the study, the subject orally received BRL25000 ES-600 (equivalent to CVA 6.4 mg/kg/day and AMPC 90 mg/kg/day) in two divided doses for 7 days (treatment phase), and then was observed for 7 days (post-therapy observation phase). The planned duration of participation in the study was 14 days in total. Objectives: To assess the efficacy and safety of BRL25000 ES-600 [clavulanic acid (CVA)/amoxicillin (AMPC) = 6.4/90mg/kg/day (in terms of potency)] administered to pediatric patients with otitis media in two divided doses for 7 days, and to verify the validity of the clinical dosage. Primary Outcome/Efficacy Variable: 1.Clinical response determined according to the Japanese criteria 2.Bacteriological response determined according to the Japanese criteria 3.Safety: subjective symptoms/objective signs, gastrointestinal symptoms (diarrhea/loose stools), laboratory test values. Secondary Outcome/Efficacy Variable(s): 1.Improvement 2.Clinical response determined according to the overseas criteria 3.Bacteriological response determined according to the overseas criteria 4.Pharmacokinetics: plasma drug concentration, MEF (otorrhea) drug concentration Statistical Methods: Efficacy analyses: The percentage of go od in a ssessment of clinical response according to the Japanese criteria, percentage of bac teriological in assessment of bacteriological response according to the Japanese criteria, percentage of improvem ent in a ssessment of improvement, and percentage of clinical/b acteriological success in assessment of clinical/bacteriological response according to the overseas criteria as well as 95% confidence intervals (CIs) were calculated. Direct approximation was used for CI calculation. Pharmacokinetic analyses: Summary statistics were calculated for plasma CVA and AMPC concentrations at 1.5 and 4 hours post dose. The mean, SD, median, minimum, maximum, and 90% CI for mean for descriptive statistics were calculated. Study Population: Patients meeting following key criteria were eligible for enrolment. There was no restriction as to sex or hospitalization (inpatient/outpatient) status. 1.Target disease: Patients with ac ute suppurative otitis media or ac ute exacerbation of chronic suppurative otitis media, di agnosed on the basis of the otoscopic findings described in 1) or 2) below: 1
2 1) Within 48 hours after the finding of purulent otorrhea 2) Middle ear effusion as evidenced by at least two of the following:decreased or absent tympanic mobility measured by pneumatic otoscopy; Yellow or white discoloration of the tympanic membrane; Opacification of the tympanic membrane; PLUS acute inflammation as evidenced by at least one of the following: Within 48 hours after the occurrence of ear pain (including the motions of unaccustomedly tugging or rubbing the ear); Redness of the tympanic membrane or mucosa; Bulging of the tympanic membrane. 2.Age: 3 months and <12 years As key exclusion criteria, patients who applied any of the following were not enrolled in the study. 1. Patient who has a severe infection and is not considered treatable with an oral preparation; 2. Patient who is undergoing or has undergone at least one or more doses of systemic antimicrobial therapy within the last 72 hours; 3. Patient who weighs 40 kg or more; 4. Patient who has a tympanostomy tube(s) in place in the infected ear(s) or who has anatomic abnormalities potentially having continuous effects on auditory tubal functions (e.g. cleft palate, high-arched palate, Down's syndrome); 5. Patient who has otitis media cholesteatoma. BRL25000 ES-600 Number of Subjects: Planned, N >60 Treated, N 107 Completed, n (%) 99 (93) Total Number Subjects Withdrawn, N (%) 8 (7) Withdrawn due to Adverse Events n (%) 3 Withdrawn due to Lack of Efficacy n (%) 0 Withdrawn for other reasons n (%) 5 (5) Demographics (C-FAS/SP) N (FAS) 107 Females: Males 51:56 Mean Age, years (SD) 4.55 (2.83) Oriental, n(%) 106 (99) Others, n(%) 1(<1%) Population Clinical response/fas (C-FAS) 107 Bacteriological response/fas (B-FAS) 81 Clinical response according to Japanese criteria/pps 77 (JC-PPS) Bacteriological response according to Japanese 60 criteria/pps (JB-PPS) Safety population (SP) 107 Pharmacokinetic analysis population (PKAP) 32 2
3 Primary & Secondary Efficacy Results: 3
4 Clinical and Bacteriologial Responses by Pathogen Isolated Clinical response (%) (JC PPS) Pathogen isolated Fair Poor (Clinical success rate) Bacteriological Bacteriological response (%) (End of therapy visit: JB PPS) Unchanged Unknown Bacteriological rate S. pneumoniae 11/16 (69) 5/16 (31) /16 16/ /16 PPSP 8/ /8 8/ /8 PISP 3/5 (60) 2/5 (40) 0 0 5/5 5/ /5 PRSP 0 3/ /3 3/ /3 H. influenzae 17/31 (55) 12/31 (39) 1/31 1/31 29/31 (94) 30/31 0 1/31 30/30 β lactamase non producing 17/30 (57) 11/30 (37) 1/30 1/30 28/30 (93) 29/30 0 1/30 29/29 β lactamase producing 0 1/ /1 1/ /1 M. (B.) catarrhalis 3/5 (60) 1/5 (20) 1/5 (20) 0 4/5 (80) 4/5 0 1/5 4/4 S. pyogenes 0 1/ /1 1/ /1 S. aureus 1/4 (25) 2/4 (50) 1/4 (25) 0 3/4 (75) 2/4 2/4 0 2/4 (50) Bacteriological rradication rate (%) = ( Bacteriological Eradication / (N Unknown )) 100 Bacteriological and Clinical Responses in Patients with Multiple Pathogens Bacteriological response (JB PPS) Pathogens isolated (β lactamase) On therapy visit End of therapy visit S. pneumoniae / P. aeruginosa (+) Unknown / Unknown / H. influenzae ( ) / S. aureus (+) Unchanged / Unchanged / H. influenzae ( ) / Staphylococcus sp ( ) / / H. influenzae ( ) / Staphylococcus sp (+) / / Unchanged M. catarrhalis (+) / P. aeruginosa (+) / / M. catarrhalis (+) / Staphylococcus sp (+) / Unknown / Unknown S. pneumoniae / H. influenzae ( ) / M. catarrhalis (+) / / / / S. pneumoniae / H. influenzae ( ) / Staphylococcus sp ( ) Unchanged / Bacteriological / / Bacteriological / S. aureus (+) / Streptococcus sp ( ) / Corynebacterium sp / / / / S.pyogenes / Staphylococcus sp ( ) / Corynebacterium sp / / / / Clinical response (JC PPS) Fair Improvement (S. pneumoniae; C-FAS) 4
5 Plasma AMPC and CVA concentrations 1.5hr (n=19) 4hr (n=18) Plasma AMPC concentrations, Mean µg/ml (SD) 16.8 (6.5) 6.9 (5.09) Plasma CVA concentrations, Mean µg/ml (SD) 2.1 (0.87) 0.5 (0.43) Safety Results: Most Frequent Adverse Events - On-Therapy n (%) Subjects with any AE(s), n(%) 49 (46%) diarrhea NOS 37 (35%) vomiting NOS 4 (4%) loose stools 2 (2%) eczema 2 (2%) dermatitis contact 2 (2%) pyrexia 2 (2%) nasopharyngitis 1 (<1%) influenza 1 (<1%) Serious Adverse Events - On-Therapy n (%) [n considered by the investigator to be related to study medication] Subjects with non-fatal SAEs, n (%) 0 Subjects with fatal SAEs, n (%) 0 Conclusion: The present study demonstrated excellent clinical and bacteriological efficacy of BRL25000 ES- 600 against the major pathogens of acute otitis media - S. pneumoniae, H. influenzae, and M. catarrhalis. The clinical and bacteriological responses were high even against penicillin-resistant and int ermediate S. pneumoniae (PRSP, PISP), as against penicillin-susceptible S. pneumoniae. BRL25000 ES-600 showed high clinical and bacteriological success rates in multiple (2 or 3 strains) infection, including β-lactamase producing strains. In safety evaluation, diarrhea/loose stools associated with changes in the nature of the stool occurred, but all the cases were considered clinically treatable or less severe than those of clinical concern. Publications: J. New Rem.&Clin. Vol.54 No : Updated: 24Nov08 5
Definitions of Otitis Media
Definitions of Otitis Media T H I S T E A C H I N G P R E S E N T A T I O N F O R T H E I S O M W E B S I T E H A S B E E N P R E P A R E D B Y T A L M A R O M, M D A N D S H A R O N O V N A T T A M I
More informationEvelyn A. Kluka, MD FAAP November 30, 2011
Evelyn A. Kluka, MD FAAP November 30, 2011 > 80% of children will suffer from at least one episode of AOM by 3 years of age 40% will have > 6 recurrences by age 7 years Most common diagnosis for which
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationACUTE PAEDIATRIC EAR PRESENTATIONS PROF IAIN BRUCE PAEDIATRIC OTOLARYNGOLOGIST & ADULT OTOLOGIST
www.manchesterchildrensent.com ACUTE PAEDIATRIC EAR PRESENTATIONS PROF IAIN BRUCE PAEDIATRIC OTOLARYNGOLOGIST & ADULT OTOLOGIST A CHILD WITH EARACHE UNCOMPLICATED AOM ACUTE OTITIS MEDIA Acute otitis media
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationvaccination. Children enrolled in these clusters between 6 weeks and 6 months of age received a 2-dose primary vaccination schedule.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationComparative Efficacy and Safety Evaluation of Cefaclor VS Amoxycillin + Clavulanate in Children with Acute Otitis Media (AOM)
Special Article Comparative Efficacy and Safety Evaluation of Cefaclor VS Amoxycillin + Clavulanate in Children with Acute Otitis Media (AOM) Mukesh Aggarwal, Ramanuj Sinha 1, M. Vasudeva Murali 2, Prita
More informationmg 25 mg mg 25 mg mg 100 mg 1
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTIPRIO safely and effectively. See full prescribing information for OTIPRIO. OTIPRIO (ciprofloxacin
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSTUDY SELECTION AND DATA EXTRACTION:
Pediatrics Treatment and Prevention of Otitis Media John Erramouspe and Catherine A Heyneman OBJECTIVE: To review and summarize recent advances in the treatment and prevention of otitis media (OM). DATA
More informationStudy No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study
Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory
More informationDefinition. Otitis Media with effusion (OME)
Otitis Media. 1 Dr,wegdan saeed ALFHAL 2 Definition Acute Otitis Media (AOM) acute onset of symptoms, evidence of a middle ear effusion, and signs or symptoms of middle ear inflammation. Otitis Media with
More informationReceived 18 May 2011/Returned for modification 4 July 2011/Accepted 13 August 2011
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2011, p. 5022 5026 Vol. 55, No. 11 0066-4804/11/$12.00 doi:10.1128/aac.00692-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparison
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAcute Otitis Media, Acute Bacterial Sinusitis, and Acute Bacterial Rhinosinusitis
Acute Otitis Media, Acute Bacterial Sinusitis, and Acute Bacterial Rhinosinusitis This guideline, developed by Larry Simmons, MD, in collaboration with the ANGELS team, on October 3, 2013, is a significantly
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Nonsevere acute otitis media: a clinical trial comparing outcomes of watchful waiting versus immediate antibiotic treatment McCormick D P, Chonmaitree T, Pittman C, Saeed K, Friedman N R, Uchida T, Baldwin
More informationAcute otitis media (AOM) is the most common bacterial
ORIGINAL STUDIES A Multicenter, Open Label, Double Tympanocentesis Study of High Dose Cefdinir in Children With Acute Otitis Media at High Risk of Persistent or Recurrent Infection Adriano Arguedas, MD,*
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections
Ceftriaxone sodium Rapid onset, sustained action, for a broad spectrum of infections 1, 2, 3 Antibiotic with a broad spectrum of activity Broad spectrum of activity against gram-positive* and gram-negative
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : LEVOFLOXACIN Study number : LOFBO-OTMD-002 Study title : A Multicenter, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Levofloxacin in the Treatment of Children Who
More informationUpper Respiratory Tract Infections / 42
Upper Respiratory Tract Infections 1 Upper Respiratory Tract Infections Acute tonsillitispharyngitis Acute otitis media Acute sinusitis Common cold Acute laryngitis Otitis externa Mastoiditis Acute apiglottis
More informationThe Turkish Journal of Pediatrics 2007; 49:
The Turkish Journal of Pediatrics 2007; 49: 390-396 Original The comparison of single-dose ceftriaxone, five-day azithromycin, and ten-day amoxicillin/clavulanate for the treatment of children with acute
More informationSecondary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAXITAB-CV TAB. COMPOSITION :
AXITAB-CV TAB. COMPOSITION : Each film coated tablet contains: Cefuroxime Axetil I.P. Eq. to Anhydrous 500mg. Potassium Clavulanate Diluted I.P. Eq. to Clavulanic Acid 125mg DESCRIPTION : Cefuroxime Axetil
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Tähtinen PA, Laine MK, Huovinen P, et al. A placebo-controlled
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSoleus 75 (6 ml) 0 (6 ml) 75 (6 ml. Tibialis posterior 75 (6 ml) 0 (6 ml) 75 (6 ml) Total 300 (24 ml) 0 (24 ml) 300 (24 ml) Dose: U (solution volume)
Study No.: BTX108512 Title: A Multicenter Study to Evaluate the Efficacy and Safety in Patients with Post-Stroke lower Limb Spasticity Receiving a Double-Blind, -Controlled GSK1358820 Treatment Followed
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Acute Otitis Media. These podcasts are designed to give medical students an overview of key topics in pediatrics. The
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationJapanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGuidance for Industry Acute Bacterial Otitis Media: Developing Drugs for Treatment
Guidance for Industry Acute Bacterial Otitis Media: Developing Drugs for Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationUPPER RESPIRATORY TRACT INFECTIONS. IAP UG Teaching slides
UPPER RESPIRATORY TRACT INFECTIONS 1 INTRODUCTION Most common problem in children below 5 years. In this age group they get about 6 8 episodes per year. It includes infections of nasal cavity, throat,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationReview Article Pneumococcal Conjugate Vaccines and Otitis Media: An Appraisal of the Clinical Trials
International Journal of Otolaryngology Volume 2012, Article ID 312935, 15 pages doi:10.1155/2012/312935 Review Article Pneumococcal Conjugate Vaccines and Otitis Media: An Appraisal of the Clinical Trials
More informationHigh dose amoxicillin for sinusitis
High dose amoxicillin for sinusitis Amoxil ( amoxicillin ) is a commonly used penicillin antibiotic. It is produced in tablets (500 mg 875 mg), capsules, chewable tablets and oral suspensions. 6-3-2018
More informationPFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Periods: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUpper Respiratory Tract Infections
Upper Respiratory Tract Infections OTITIS MEDIA Otitis media is an inflammation of the middle ear. There are more than 709 million cases of otitis media worldwide each year; half of these cases occur in
More information97 80 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
4 4 9 6 6 6 7 6 66 4 99.9.7 8. 7..8.4..7.9.. 4. 7.4 8.7 99 97 8 Streptococcus pneumoniae, Haemophilus influenzae, oraxella catarrhalis 4 4 64 7 9 7 89. RT PCR 4. 6 46. Key words: RT PCR I 6 6 46 64. 8.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMenC. MenW MenY
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBeta-lactamase production should have no effect on Azithromycin activity.
AZIMEX Composition Azimex 250 Capsules Each capsule contains Azithromycin (as dihydrate) 250 mg Capsules & Powder Azimex 500 mg Capsules Each capsule contains Azithromycin (as dihydrate) 500 mg Azimex
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAnalysis of immunogenicity
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOTIPRIO an antibiotic medicine given to your child at the time of ear tube surgery
Bring this Conversation Starter with you to your child s next doctor appointment an antibiotic medicine given to your child at the time of ear tube surgery Use this questionnaire to start a conversation
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe Bacteriology of Bronchiectasis in Australian Indigenous children
The Bacteriology of Bronchiectasis in Australian Indigenous children Kim Hare, Amanda Leach, Peter Morris, Heidi Smith-Vaughan, Anne Chang Presentation outline What is bronchiectasis? Our research at Menzies
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAnalysis of safety The analysis was performed on the Total Vaccinated cohort.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Study vaccines Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHow to Order OTIPRIO (ciprofloxacin otic suspension) 6%
How to Order (ciprofloxacin otic suspension) 6% Product: (ciprofloxacin otic suspension) 6% Each carton contains 1 ml of 6% (60 mg/ml, w/v) ciprofloxacin in a 2 ml single-patient use glass vial fitted
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChoosing an appropriate antimicrobial agent. 3) the spectrum of potential pathogens
Choosing an appropriate antimicrobial agent Consider: 1) the host 2) the site of infection 3) the spectrum of potential pathogens 4) the likelihood that these pathogens are resistant to antimicrobial agents
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1)
Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate () (mcg strength) bd via DISKUS/ACCUHALER
More informationAlloiococcus otitidis: a neglected bacterium in otitis media
Alloiococcus otitidis: a neglected bacterium in otitis media School of Health Sciences University of Newcastle HAPS Immunology and Genetics Newcastle Australia The team in alphabetical order Chris Ashhurst-Smith
More informationThe importance of considering BACTERIAL LOAD in OTITIS MEDIA research
The importance of considering BACTERIAL LOAD in OTITIS MEDIA research Heidi Smith-Vaughan, Robyn Marsh, Michael Binks, Mirjam Kaestli, Peter S Morris, Amanda J Leach OM in Indigenous children OM is endemic
More informationStudy No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOtitis media: a review for the Family physician
Otitis media: a review for the Family physician Rehab Alwotayan 1, Khaled Alabdulhadi 1 Otitis media (OM) is a serious healthcare concern worldwide. Acute otitis media is over-diagnosed. Symptoms are neither
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationGSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and nonapproved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationWebposting Clinical Trial Results Synopsis
Study Summary This summary information is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This summary information is not intended to replace
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg
ZINEX Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg Tablets Action Cefuroxime axetil owes its bactericidal activity to the parent compound cefuroxime. Cefuroxime is a well-characterized
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGuideline Review. Clinical Practice Guideline on the Diagnosis and Management of Acute Otitis Media BCC LAM, YC TSAO, Y HUI.
HK J Paediatr (new series) 2006;11:76-83 Guideline Review Clinical Practice Guideline on the Diagnosis and Management of Acute Otitis Media BCC LAM, YC TSAO, Y HUI Introduction Acute otitis media is a
More informationStudy No.: Title: Rationale: Phase Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information